WILSONVILLE, Ore. (AP) — An Oregon Medicaid committee on Thursday significantly scaled back access to an effective — but expensive — new drug used to treat hepatitis C.
The decision allows only a narrow set of Medicaid patients to be treated with the $1,000-per-pill drug known as Sovaldi, made by Gilead Sciences Inc.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.